Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) is projected to post its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Kiora Pharmaceuticals to post earnings of ($0.38) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.
Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.13.
Kiora Pharmaceuticals Stock Performance
Shares of NASDAQ:KPRX opened at $1.66 on Thursday. The company’s fifty day simple moving average is $2.44 and its 200 day simple moving average is $2.40. Kiora Pharmaceuticals has a 12 month low of $1.55 and a 12 month high of $2.91.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kiora Pharmaceuticals in a research report on Monday, October 12th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has an average rating of “Sell”.
Read Our Latest Report on KPRX
Kiora Pharmaceuticals Company Profile
Kiora Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases of the eye. The company’s research programs are aimed at addressing conditions with limited treatment options, including inherited retinal diseases and inflammatory eye disorders.
Kiora’s lead program, KIO-301, is an investigational small-molecule therapy designed to function as a molecular photoswitch. The company is studying its potential to restore light perception in patients with vision loss caused by retinal degeneration, including retinitis pigmentosa.
Read More
- Five stocks we like better than Kiora Pharmaceuticals
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
